tradingkey.logo
tradingkey.logo
Search

Rapport Therapeutics Inc

RAPP
Add to Watchlist
40.980USD
-1.800-4.21%
Close 07-31 16:00ETQuotes delayed by 15 min
1.96BMarket Cap
LossP/E TTM

RAPP Income Statement

You can find the annual or quarterly income statement of Rapport Therapeutics Inc here for insights into the performance and operational efficiency of Rapport Therapeutics Inc.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
Total revenue
--20.00M
----
----
----
----
----
----
----
----
----
----
----
----
Revenue
--20.00M
----
----
----
----
----
----
----
----
----
----
----
----
Operating expenses
63.11%44.22M
63.72%38.51M
38.57%29.99M
41.81%29.50M
58.58%27.11M
58.99%23.52M
126.27%21.64M
213.73%20.80M
229.30%17.09M
--14.79M
--9.56M
--6.63M
--5.19M
R&D expenses
67.16%32.72M
75.93%30.26M
43.34%22.28M
44.56%22.68M
56.53%19.57M
45.77%17.20M
105.05%15.54M
232.32%15.69M
220.70%12.50M
--11.80M
--7.58M
--4.72M
--3.90M
Depreciation, depletion, and amortization
-6.97%227.00K
1.92%265.00K
36.99%300.00K
44.23%300.00K
22.00%244.00K
390.57%260.00K
852.17%219.00K
890.48%208.00K
1233.33%200.00K
--53.00K
--23.00K
--21.00K
--15.00K
Operating profit
10.67%-24.21M
-63.72%-38.51M
-38.57%-29.99M
-41.81%-29.50M
-58.58%-27.11M
-58.99%-23.52M
-126.27%-21.64M
-213.73%-20.80M
-229.30%-17.09M
---14.79M
---9.56M
---6.63M
---5.19M
Net non-operating interest income (expenses)
Non-operating interest income
43.12%4.36M
34.03%4.75M
-25.40%3.06M
3.17%2.76M
67.77%3.04M
157.53%3.54M
379.32%4.10M
1112.22%2.68M
2320.00%1.81M
--1.38M
--856.00K
--221.00K
--75.00K
Special income (expenses)
----
--0.00
--0.00
----
100.00%0.00
100.00%0.00
--0.00
--0.00
-617.48%-7.39M
---94.00K
----
----
---1.03M
Income before tax
17.48%-19.86M
-68.98%-33.76M
-53.53%-26.93M
-47.52%-26.73M
-6.15%-24.06M
-47.86%-19.98M
-101.39%-17.54M
-182.74%-18.12M
-268.84%-22.67M
---13.51M
---8.71M
---6.41M
---6.15M
Income tax
----
----
----
----
--0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
-100.00%0.00
--6.00K
--1.00K
--2.00K
--1.00K
Income after tax
17.48%-19.86M
-68.98%-33.76M
-53.53%-26.93M
-47.52%-26.73M
-6.15%-24.06M
-47.79%-19.98M
-101.37%-17.54M
-182.65%-18.12M
-268.78%-22.67M
---13.52M
---8.71M
---6.41M
---6.15M
Net income from continuous operations
17.48%-19.86M
-68.98%-33.76M
-53.53%-26.93M
-47.52%-26.73M
-6.15%-24.06M
-47.79%-19.98M
-101.37%-17.54M
-182.65%-18.12M
-268.78%-22.67M
---13.52M
---8.71M
---6.41M
---6.15M
Net income attributable to controlling interests
17.48%-19.86M
-68.98%-33.76M
-53.53%-26.93M
-47.52%-26.73M
-6.15%-24.06M
-47.79%-19.98M
-101.37%-17.54M
-182.65%-18.12M
-268.78%-22.67M
---13.52M
---8.71M
---6.41M
---6.15M
Net income attributable to common shareholders
17.48%-19.86M
-68.98%-33.76M
-53.53%-26.93M
-47.52%-26.73M
-6.15%-24.06M
-47.79%-19.98M
-101.37%-17.54M
-182.65%-18.12M
-268.78%-22.67M
---13.52M
---8.71M
---6.41M
---6.15M
Basic earnings per share
38.39%-0.42
-26.29%-0.72
-41.08%-0.71
-52.23%-0.75
-6.48%-0.68
-33.51%-0.57
-111.31%-0.50
-173.39%-0.50
-268.78%-0.64
---0.43
---0.24
---0.18
---0.17
Diluted earnings per share
38.39%-0.42
-26.29%-0.72
-41.08%-0.71
-52.23%-0.75
-6.48%-0.68
-33.51%-0.57
-111.31%-0.50
-173.39%-0.50
-268.78%-0.64
---0.43
---0.24
---0.18
---0.17
Dividend per share
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
--0.00
Currency unit
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
----
----
----
----
----
----
----
----

FAQs

How do I read Rapport Therapeutics Inc's income statement on TradingKey?

Start with total revenue, then review cost of revenue, gross profit, operating expenses, operating profit, income before tax, net income, and EPS. Revenue shows the scale of the business, while margins and profit lines show whether that revenue is being converted into earnings efficiently.

What is the difference between quarterly and annual income statements?

A quarterly income statement shows performance for a three-month fiscal period, while an annual income statement summarizes the full fiscal year. Quarterly data is useful for tracking recent momentum and seasonality, while annual data is better for judging long-term growth, profitability, and business cycles.

What does YOY mean on the income statement page?

YOY means year over year. It compares a financial metric with the same period in the previous year, such as this quarter's revenue versus revenue in the same quarter last year. YOY comparison helps investors see growth trends while reducing the impact of normal seasonal changes.

Which income statement metrics matter most when analyzing RAPP stock?

Important metrics include revenue growth, gross profit, gross margin, operating profit, operating margin, net income, EPS, R&D expenses, SG&A expenses, and tax expense. Investors usually look at these together to judge whether the company is growing, controlling costs, and improving profitability.

What was Rapport Therapeutics Inc's net income for the year?

Rapport Therapeutics Inc posted -111.48M in net income for fiscal year 2025.

How much net income did Rapport Therapeutics Inc post in the last quarter?

Rapport Therapeutics Inc reported -19.86M in net income for the latest quarter。

What was Rapport Therapeutics Inc's annual operating profit?

Rapport Therapeutics Inc's operating income was -125.10M for fiscal year 2025.

How is EPS related to the income statement?

EPS, or earnings per share, is based on net income divided by the number of shares outstanding. It helps investors understand how much profit the company generated for each share, but it should be reviewed alongside share count changes, margins, cash flow, and valuation metrics.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.